Additionally, a phase II study (NCT00190424) attempted to deliver a TLR9 agonist (oligodeoxynucleotides containing CpG motifs, CpG-ODN) to the brain to treat recurrent glioblastoma; disappointingly, this strategy was proved ineffective (103). Here, TLR9 is linked to glioblastoma.